Conatus Pharmaceuticals prices upsized IPO at $11 midpoint

By
A A A

Conatus Pharmaceuticals, a biotech in Phase 2 trials developing treatments for chronic liver disease, raised $66 million by offering 6 million shares (20% more than the 5 million originally planned) at $11, the midpoint of the $10-$12 range. Conatus Pharmaceuticals plans to list on the NASDAQ under the symbol CNAT. Stifel and Piper Jaffray acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CNAT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Lies Retailers Tell
Lies Retailers Tell                 

Stocks

Referenced

Most Active by Volume

38,630,431
  • $42.65 ▲ 6.15%
28,683,063
  • $103.77 ▲ 1.27%
22,834,195
  • $8.205 ▲ 0.43%
21,368,821
  • $16.655 ▲ 0.33%
16,805,574
  • $79.82 ▲ 1.44%
15,262,910
  • $12.52 ▲ 4.07%
14,727,803
  • $97.24 ▲ 0.38%
13,356,462
  • $13.355 ▲ 1.17%
As of 10/22/2014, 11:33 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com